Introduction
Meningiomas constitute approximately 20% of primary intracranial tumours (1) . The World Health Organization (WHO) classifies them into three grades based on histopathological criteria. Most, defined as grade I, are benign and do not recur after surgical resection, while atypical (grade II) and anaplastic (grade III) tumours have worse clinical outcomes, with frequent recurrence. However, some low-grade meningiomas also recur despite complete resection. Biological markers, such as increased expression of cathepsin-B and cathepsin-L antigens (2), S100A5 protein (3) or c-myc (4) and loss of expression of progesterone receptor (5) and tumour suppressor in lung cancer-1 (6), have been identified as predictors of recurrence in grade I meningioma. Moreover, the presence of cytogenetic aberrations in meningiomas might also be linked to increased invasive potential (7) . More than 60% of meningiomas show mutation or loss of heterozygosity in the NF2 gene and these events are more frequent in fibroblastic and transitional meningiomas than in the meningothelial subtype (8) . These alterations in the NF2 gene seem to be histotype-, but not grade-related (9, 10) . Transcriptome profiles of meningiomas have been reported that showed a subset of genes differentially expressed in WHO grade I compared to WHO grades II and III (11) , but, in this study, two high-grade meningiomas had expression profiles very similar to that of the non-neoplastic meninges. Another study reported differences in gene expression between WHO grades II and III, but supervised classification of the tumours did not reveal specific expression patterns for each WHO grade (12) . Finally, a study using combined gene expression microarrays and array comparative genomic hybridization showed that meningiomas of all three grades fall into two main molecular groups referred to as low-and high-proliferative meningiomas (13) .
RNA extraction. Total RNA, extracted from the samples using the RNA Plus procedure (Qbiogen, Illkirch, France) based on the method of Chomczinski and Sacchi (14) , was precipitated with ethanol. The quality of the isolated total RNA was evaluated on nanochips using an Agilent 2100 Bioanalyzer (Agilent Technologies, Massy, France). RNA from a whole normal adult male human brain (single donor, 72 years) in 0.1 mM EDTA, pH 8.0, was purchased from Stratagene (Stratagene Europe, Amsterdam, The Netherlands).
RNA amplification. Total RNA (2 μg) was amplified and biotin-labelled by a round of in vitro transcription using a MessageAmp aRNA kit (Ambion, Austin, TX, USA) following the manufacturer's protocol. Before amplification, spikes of different concentrations of synthetic mRNA were added to all samples and were used to determine the quality of the process. aRNA yield was measured with a UV spectrophotometer and the quality verified on nanochips using the Agilent 2100 Bioanalyzer.
Array hybridization and processing. Biotin-labelled aRNA (10 μg) from 17 meningiomas were fragmented using 5 μl of fragmentation buffer in a final volume of 20 μl, then mixed with 240 μl of Amersham hybridization solution (GE Healthcare Europe GmbH, Saclay, France) and injected on to CodeLink Uniset Human Whole Genome Bioarrays containing 55,000 human oligonucleotide geneprobes (GE Healthcare Europe GmbH). The arrays were hybridized overnight at 37˚C at 15 g in an incubator, then washed in stringent TNT buffer at 46˚C for 1 h before performing the streptavidin-cy5 (GE Healthcare) detection step. Each array was incubated for 30 min in 3.4 ml of streptavidin-cy5 solution as previously described (15) , washed four times in 240 ml of TNT buffer, rinsed twice in 240 ml of water containing 0.2% Triton X-100, then dried by centrifugation at 650 x g. The arrays were scanned using a Genepix 4000B scanner (Axon, Union City, CA, USA) and Genepix software, with the laser set at 635 nm, the laser power at 60% and the photomultiplier tube voltage at 60%. The scanned image files were analysed using CodeLink expression software, version 4.0 (GE Healthcare), which produces both a raw and a normalized hybridization signal for each spot on the array.
Microarray data analysis. CodeLink software was used to normalize the raw hybridization signal on each array to the median of the array (median intensity is 1 after normalization) for better cross-array comparison. The threshold of detection was calculated using the normalized signal intensity of the 100 negative control samples in the array; spots with signal intensities below this threshold were referred to as 'absent'. The quality of processing was evaluated by generating scatter plots of positive signal distribution. Signal intensities were then converted to the log base 2 values. The expression of the genes in the normal brain was used as the standard and set to 1.
Real-time RT-PCR.
RNA samples (0.5 μg) from tumours and the normal whole brain were heated for 3 min at 75˚C, then immediately placed on ice. First-strand DNA was synthesized by incubating the RNA with 0.5 mM of each dNTP, 10 mM DTT, 40 U of RNA-sin (Promega), 20 μM random hexamers, and 200 U of Moloney murine leukaemia virus (M-MLV) reverse transcriptase (In Vitrogen, Cergy-Pontoise, France) for 90 min at 42˚C in a final volume of 20 μl of reverse transcriptase buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl and 3 mM MgCl 2 ). The volume was then made to 100 μl with distilled water. Negative controls were performed by replacing the enzyme with water.
PCR was performed on a LightCycler instrument (Roche Diagnostics, Mannheim, Germany). cDNA samples (2, 0.2 and 0.02 μl) were diluted in glass capillaries to a volume of 20 μl with PCR mix (LightCycler Faststart DNA Master Plus SYBR-Green 1, Roche Diagnostics) containing a final concentration of 4 mM MgCl 2 and 0.5 μM 3'-and 5' primers. The oligonucleotide sequences corresponding to selected gene transcripts were designed using Primer 3 software (Infobiogen, Villejuif, France) and are available on request from the authors. The cDNA was denatured for 8 min at 95˚C, then amplified by 40-50 cycles of 15 s at 95˚C, 5 s at 62˚C and 10 s at 72˚C. After amplification, the temperature was slowly raised above the melting temperature of the PCR products to measure the fluorescence for the melting curve, demonstrating the purity of the transcripts by their respective melting temperatures. Non-specific products, such as primer dimers, could be readily distinguished from the product by their lower melting point. Negative controls were also analyzed. The results were calculated from the crossing-point values and expressed as the amount of test gene product relative to the amount of GAPDH product, used as a housekeeping gene, for the same sample. To verify the presence of a single PCR product of the correct size, the product was electrophoresed for 1 h at 70 V in 0.5X Tris-borate-EDTA buffer, pH 8.3, on a 2% agarose gel (Tebu, Le Perray-enYvelines, France), the DNA band being visualized using ethidium bromide in the presence of a DNA molecular weight standard (100 bp, Promega) under UV illumination.
Statistical analysis was performed using the Wilcoxon test.
Results
Clinical data and histological features. The clinicopathological data and histological findings for the 23 patients are shown in Table I . According to the current WHO classification, 10 tumours were grade I (3 meningothelial, 4 fibroblastic and 3 transitional), 6 grade II (atypical) and 7 grade III (anaplastic). All tumours were surgically completely resected. Thirteen recurrences were seen after surgery and one was multi-focal in a patient with grade III tumour. Of the 10 patients with WHO grade I tumours, 7 had benign tumours with a very low proliferative index (Ki-67 <2%) or with no, or only one, mitosis per 10 high power field (HPF). Of these 7, only one (case 10) had a recurrence. The other 3 of the 10 cases also had benign neoplasms, but with either a higher proliferative index (Ki-67 =3) or more than one mitosis per 10 HPF and all 3 showed recurrence.
Global gene expression pattern. The unsupervised hierarchical cluster of the 17 meningiomas analysed by microarray (10 grade I, 5 atypical grade II and 2 anaplastic grade III) using the level of expression of the 53429 genes classified the neoplasms into three groups, as shown in the dendrogram in Fig. 1 . Group A consisted of 7 cases with grade I meningiomas, group B consisted of the 3 cases with grade I meningiomas with higher proliferation indexes and/or recurrence (cases 3, 7 and 10) plus the 5 grade II meningiomas, while group C consisted of the 2 grade III meningiomas.
Analysis of genes differentially expressed between the three meningioma groups. Of all the genes on the microarray, 346 and 2995 showed ≥2-fold over-expression in group B and group C, respectively, compared to group A. The number of genes under-expressed by ≥2-fold was, respectively, 184 and 1380 in group B and group C compared to group A. Comparing meningiomas in groups B and C, 1953 genes were upregulated and 508 downregulated in group B (fold change ≥2). Only 24 genes were upregulated with a fold change of ≥2 in both groups B and C compared to group A (listed in Table II) . These included 5 genes (CD44, COL6A3, COL7A1, LAMA5 and LOX) involved in cell adhesion, 5 (CKS2, CCNB1, BIRC5, PLK2 and UBEC2C) involved in cell division, one (Notch1) involved in cell proliferation/ Table I . Clinical and morphological data for the 23 patients. 
nd, not done; for surgery, + represents complete exeresis; GEP, gene expression profile. Table II . Genes upregulated (fold change ≥2 compared to group A) in both groups B and C; mean adjusted intensity for each group ± standard error of the mean.
- Table III . Genes downregulated (fold change ≥3 compared to group A) in both groups B and C; mean adjusted intensity for each group ± standard error of the mean. Amino acid transport Of the genes which only showed differential expression in group C compared to group A, 15 are presented in Table IV . The fold change for these 15 genes ranged from 3.5 to 11.1 for the upregulated genes and from 3.4 to 42.5 for the downregulated genes. Of the former group, 3 (JUNB, FSTL1 and Slit-2) are tumour suppressor genes.
Analysis of genes showing differential expression between fibroblastic and meningothelial meningiomas.
Genes upregulated (>5-fold) in one histotype compared to the other are listed in Table V . The 10 genes which showed the greatest upregulation in fibroblastic meningiomas coded for extracellular matrix proteins. In addition, ERBB4, a member of the EGF receptor family, was also upregulated. In contrast, the genes upregulated in the meningothelial meningiomas encoded proteins with different functions. Three tumour suppressor genes (DEFB1, MLPH and FAT3), present only in very low amounts in fibroblastic variants, were over-expressed more than 20-fold. Several genes considered as targets of the Wnt/ß-catenin signalling pathway (EDN3, DSG2, APCDD1, NPM2, NF2 and NEDD4L) were upregulated, as were three genes (SSTR2, HOPS and NF2) known to be implicated in the tumorigenesis of the meningothelial subtype. Interestingly, all transitional meningiomas presented intermediate mRNA levels between fibroblastic and meningothelial tumour levels.
qRT-PCR validation of differential gene expression. Of the 6 examined by qRT-PCR, 4 transcripts (HOPS, MMP9, ARHGAP28
and SPON2) examined in 22 tumours (6 lowgrade, 9 atypical and 7 anaplastic meningiomas) showed similar patterns of differential expression between group A and group B or C meningiomas to those seen on the microarray, the differences between the tumour groups being statistically significant (Fig. 2) . In addition, the expression of UBE2C and TFPI2 transcripts in the 3 groups of meningiomas showed the same pattern as that obtained by microarray, but the differences did not reach significance.
Discussion
Gene expression profiling of meningiomas belonging to the three malignancy grades allowed their classification into three molecular groups, one of low-grade meningiomas (group A), one of low-grade tumours presenting recurrence and atypical meningiomas (group B) and one of anaplastic meningiomas (group C). Some previous attempts at profiling the expression pattern of meningiomas were sometimes unable to reliably distinguish the different grades of meningiomas and to identify specific expression patterns for each grade (11, 12) . Another showed that atypical meningiomas were not a molecularly distinct group of tumours and the authors concluded that they were similar to either benign or malignant meningiomas (13) .
We focused on genes showing differential expression between these 3 groups of tumours and, more particularly, between benign meningiomas and the two other groups. We found several genes that could be potential candidates for markers for classifying the different types of meningiomas. Interestingly, the 3 patients with grade I meningiomas that were placed in group B presented a recurrence and two of the tumours showed a higher number of mitoses than usual for low-grade tumours. Previous reports have suggested a subdivision of grade I meningiomas, namely the identification of a subgroup with a higher risk of recurrence (3,16-18 ). Moreover, based on c-myc expression and the clinical and histological features of the tumours, two groups of low-grade meningiomas have been defined (4) . Finally, it has been shown by molecular classification that atypical meningiomas can be classed with benign meningiomas (13) , suggesting that the molecular signature approach takes more into account the biological heterogeneity of meningiomas, which is not clearly defined by histopathological criteria.
We identified several genes that may represent progressionassociated markers. Among the genes upregulated in nonbenign meningiomas or in those benign meningiomas presenting recurrence, 3 (CKS2, UBE2C and TFPI2) were already known to be overexpressed in grade II or grade III meningiomas (13) . Numerous reports have demonstrated that CKS2 expression is frequently elevated in tumours of different tissue origins, including metastatic colon cancer (19), high- Table IV . Selected genes up-or downregulated (fold change ≥2 compared to group A) in group C, but not in group B; mean adjusted intensity for each group ± standard error of the mean.
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grade gliomas (20, 21) and prostate cancer (22) ; in these prostate tumour cells, aberrant CKS2 expression may promote tumorigenicity by protecting the cells from apoptosis (22) . UBE2C expression has frequently been correlated with tumour grade. This gene has been shown to be overexpressed in malignant breast carcinomas (23) , in hepatocellular carcinoma, in which it is associated with tumour progression (24) , in anaplastic thyroid carcinomas, in which it plays a role in thyroid cell proliferation (25) , and in high-grade glial tumours (26) . Since proteasome inhibitors have been considered as possible drugs for the chemotherapy of various tumours, new perspectives for the treatment of high-grade meningiomas based on the suppression of UBE2C function might be proposed. Moreover, several of the overexpressed genes play a role in cell adhesion. Strong CD44 expression has been demonstrated in atypical meningioma cells (27) , but no correlation between CD44 immunolabelling and tumour grade was observed in another report on meningiomas (28) . Upregulation of CD44 in cultures of meningiomas has been demonstrated by microarray (29) . The expression of this hyaluronate receptor transcript may support a role of this molecule in the invasive growth potential of neoplastic cells. In addition, the role of LOX as a promoter of metastasis has been well documented in different types of tumours (30) but upregulation of its transcript according to the grade of meningioma has not been previously reported. Transcript levels of 39 genes were downregulated in both group B and C meningiomas, possibly corresponding to a loss of differentiation of neoplasms in these 2 groups. Of these, 7 have already been described as tumour suppression genes showing decreased expression in high-grade neoplasms. Expression of LRP1B, which belongs to the low density lipoprotein receptor gene family, is inactivated by genetic and transcript alterations in non-small cell lung cancer (31) or altered by deletion in high-grade urothelial cancer (32) and the region of the chromosome containing the gene is frequently deleted in squamous cell cervical carcinoma (33) . Loss of DDR1, originally named TU3A, is also frequently seen in other high-grade tumours, such as renal cell carcinoma (34) , and downregulation of its expression may also contribute to glioma progression (35) . PLZF mRNA expression has been shown to be downregulated during melanoma progression (36) . Decreased expression of GPX3, SYNPO and TIMP3 has been previously reported in meningiomas (13) . Moreover, GPX3 is one of the genes most often downregulated or deleted in prostate cancer and this decreased expression may be associated with the aggressive behaviour of these tumours (37) . The frequent loss of expression of TIMP3 (a tissue inhibitor of matrix metalloproteinase involved in regulation of cell proliferation) as a result of genetic loss or methylation of the gene has been associated with progression of oesophageal and gastric adenocarcinomas (38) . In these neoplasms, immunohistochemical analysis showed that loss of TIMP3 expression is especially frequent in tumours with poor differentiation (38) . In meningiomas, no hypermethylation of the TIMP3 promoter has been detected (39) and no aberrant gene methylation of this gene has been reported (40) . The silencing of the TIMP3 gene or its deletion, as it is located in a genomic region, 22q12, that is frequently deleted in meningioma (41), might be involved in the progression of this neoplasm. Interestingly, our results demonstrated a dramatic downregulation of alkaline phosphatase (HOPS) mRNA expression in atypical and anaplastic meningiomas, by microarray and, in a larger number of patients by RT-PCR. This is in agreement with histoenzymological reports showing reduced levels of HOPS enzyme in high-grade meningiomas (42, 43) . Moreover, reduced HOPS protein expression had been reported in a grade I meningioma in one patient who presented recurrence after surgery (42) . In our study, the 3 grade I meningiomas which were included by molecular clustering in the group of atypical meningiomas also showed reduced HOPS transcript expression. The physiologic role of this enzyme is still poorly understood, but its detection might help in assessing risk of recurrence, especially in those borderline atypical meningiomas in which not all criteria are present for their classification as grade II. Moreover, the high expression of HOPS in meningothelial compared to fibroblastic meningiomas has not been previously described. Several other genes (SVEP1, COL8A1, LTBP2, SLO, SERPINF1, PDGFD, BMP4, LMO4, SFRP2 and SLC26A2), found to be downregulated in high-grade meningiomas in this study, have been previously reported with reduced expression in high-grade meningiomas (13) . The inhibition of expression of some of these genes has been shown to be involved in tumorigenesis; this has been demonstrated for SLO in osteosarcoma (44) , for SERPINF1 in breast cancer (45) and non-small cell lung cancer (46) and for LMO4 in several tumour types, including breast, prostate and pancreatic ductal adenocarcinomas (47) . Furthermore, the frequent presence of ADAMTSL3 mutations has been reported in colorectal cancer (48) and decreased ADAMTSL3 mRNA expression, as observed in colorectal malignancy (48) , may contribute to the progression of meningiomas. Finally, complete loss or reduced expression of AOX1, a xenobiotic metabolizing enzyme, has been reported in hepatocellular carcinomas, with a significant correlation between AOX1 expression and tumour stage (49) .
Among the genes only overexpressed in group C meningiomas compared to group A, CENPF, which encodes mitosin, a protein involved in cell cycle progression, can be considered as a marker of early recurrence in intracranial meningiomas (50) and as a prognostic factor for the recurrence of meningiomas (51) . This molecule has also been described as a biomarker associated with poor outcome in breast cancer (52) . MMP9, a component of the extracellular matrix, has been shown to be upregulated in atypical and anaplastic meningiomas (18, 53) and has been proposed as a potential target for therapy in meningiomas (54) . In contrast, the expression of SPON2, which has been shown to be overexpressed in ovarian cancer (55) , and the expression of AIM2 have not been previously reported in meningiomas. Among the genes only downregulated in group C meningiomas compared to group A, 4 (JUNB, FSTL1, TGFBR3 and MADH7) involved in the transforming growth factor-ß signalling pathway have been previously shown to be downregulated in malignant meningiomas (13) . The decreased expression of the protooncogene JUNB, a cell proliferation inhibitor and a repressor of MMP9, might explain the upregulation of MMP9 observed in high-grade meningiomas (56) . Furthermore, Slit-2 has been described as a tumour suppressor gene because it is frequently inactivated in various cancers due to hypermethylation of its promoter region (57) . Its expression has been reported to be decreased or abolished in human oesophageal squamous cell carcinomas compared to normal tissues, as shown by in situ hybridization (58) . Conflicting results on the relationship between E-cadherin expression and tumour grade have been reported in meningiomas (59) . Our data show that loss of expression of Ecadherin in meningiomas seems to be associated with increased malignancy, as previously described in an immunohistochemical study (60) .
Molecular signatures specific for different histopathological types of meningiomas, more particularly fibroblastic and meningothelial variants, have not previously been clearly identified by microarray studies. Only one recent study using unsupervised RNA cluster analysis of 27 meningiomas clustered the fibroblastic meningiomas separately from the other meningiomas and identified several genes, including BMPR1B, DMD and RAMP1, with expression signatures specific for fibroblastic meningiomas (61) . Our results confirm that several genes are differentially expressed in fibroblastic and meningothelial meningiomas. The presence of a collagenrich matrix in fibroblastic meningiomas may be due to the upregulation of several genes with an extracellular matrix function in this type of tumour. As many of these proteins, such as tenascin (62) , are expressed in the foetal meninges, their re-expression in fibroblastic meningiomas may be involved in the proliferation and adhesion of tumoral cells. Fibulin-1, known to be required for the directed migration and survival of cranial neural crest cells (63) , is present at high levels in the matrix of the leptomeningeal anlage (64) , and can suppress the motility of many types of cancer cells (65) . Meningothelial meningiomas overexpress several genes known to be tumour suppressor genes, such as ß-defensin-1, which can inhibit cancer cell proliferation in renal cell carcinoma (66) . Other genes overexpressed in meningothelial meningiomas, such as FAT3 and FAT4, encode proteins involved in cell-cell junction formation (67) . FAT4 has also been shown to be a tumour suppressor gene in breast cancer (68) . Similarly, the expression of neurofibromatosis 2 (NF2), a tumour suppressor gene, was found to be increased in meningothelial meningiomas, in agreement with previous results (4, 10) . Merlin, the protein encoded by NF2, regulates cadherin-mediated cell contacts (69) . Finally, higher expression of sst2 was also observed in meningothelial meningiomas, as reported previously (4) .
Microarray transcriptomic studies might be a useful complement to conventional diagnosis (70) . Our data on the differential expression of gene transcripts in the three groups of meningiomas remain to be validated immunohistochemically when antibodies are available for proteins such as CKS2, UBE2C, GPX3, AOX1 and SERPINF1. We are currently examining the correlation between gene expression and patient survival in a large number of meningiomas.
